Saturday 17 October 2026
Export LPCN’s income statement to Excel — free account
Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.56
0.12
−7.14%
Follow LPCN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | — | 1 |
P/E ratio |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 488.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 0.00 | — | 5.15 | 2.19 | 0.00 | 2.28 | 22.14 |
Altman Z-Score |
— | — | (8.64) | (11.57) | — | 4.31 | 4.28 | (10.45) | (0.65) | (7.74) |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (19.23) | (24.07) | — | 1.69 | 7.18 | (19.66) | (8.64) | (32.69) |
Beneish M-Score |
— | — | — | (3.46) | — | — | 1.57 | — | — | 23.60 |
P/Operating CF |
— | — | (12.43) | (3.01) | — | 9.58 | (19.97) | (7.45) | 15.31 | (14.99) |
P/B ratio |
— | — | 2.94 | 1.59 | — | 1.89 | 1.03 | 0.74 | 1.24 | 3.02 |
Price to Tangible BV |
— | — | 2.94 | 1.59 | — | 1.89 | 1.03 | 0.74 | 1.24 | 3.02 |
EV/Sales |
— | — | 0.00 | 0.00 | — | 2.71 | 0.42 | 1.72 | 0.64 | 16.06 |
EV/EBITDA |
— | — | 0.00 | 0.15 | — | 12.36 | 0.00 | 0.21 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (1.47) | 0.17 | — | (10.26) | (0.59) | 0.34 | (6.02) | (3.25) |
EV/FCF |
— | — | (1.46) | 0.17 | — | (10.20) | (0.59) | 0.34 | (5.56) | (3.22) |
Quick Ratio |
20.27 | 3.91 | 4.52 | 3.84 | 3.75 | 7.99 | 19.43 | 8.39 | 14.44 | 6.36 |
Current Ratio |
20.52 | 3.97 | 4.63 | 3.95 | 3.85 | 8.26 | 20.34 | 8.69 | 14.75 | 6.68 |
Net Debt/EBITDA |
1.42 | 1.01 | 0.87 | 0.91 | 1.06 | (11.55) | 2.66 | 1.17 | 11.94 | 1.42 |
Debt/Assets |
0.00% | 0.00% | 49.20% | 36.36% | 22.05% | 4.40% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 1.09 | 1.14 | 0.36 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.41 | 0.01 | (0.09) | 0.49 | 0.10 |
Operating CF/Net income |
0.96 | 0.80 | 1.04 | 0.90 | 0.73 | 6.95 | 1.11 | 0.73 | (145.38) | 1.01 |
Capex/Depreciation |
(0.23) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 1.19 | 0.01 | 0.14 | 0.00 |
Interest Coverage |
— | — | (24.65) | (16.83) | (46.55) | 15.47 | (447.21) | — | — | — |
| (55.80%) | (93.26%) | (82.07%) | (165.47%) | (193.85%) | (2.08%) | (26.50%) | (58.40%) | 0.04% | (54.28%) | |
| (52.18%) | (79.68%) | (50.50%) | (64.22%) | (93.15%) | (1.63%) | (23.90%) | (54.02%) | 0.04% | (48.73%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.25% | (243.95%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(73.01%) | (110.73%) | (71.37%) | (88.67%) | (111.84%) | (1.56%) | (33.01%) | (80.37%) | 0.04% | (66.61%) |
Average Days of Receivables |
0.00 | 0.00 | 32.83 | 36.50 | 0.00 | 5.59 | 58.69 | (6.70) | 6.91 | 214.12 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,510.44% | 4,526.18% | 0.00% | 47.49% | 1,711.38% | (356.93%) | 65.65% | 434.25% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 1,235.77% | 3,392.18% | 0.00% | 33.02% | 812.50% | (172.05%) | 44.66% | 190.42% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 340.58% | 627.76% | 0.00% | 3.74% | 127.22% | (22.95%) | 3.65% | 12.27% |
Graham Net Nets |
— | — | 0.34 | 0.63 | — | 0.46 | 0.88 | 1.34 | 0.80 | 0.33 |
Graham Number |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.94 | 0.00 |
Earnings Yield |
— | — | (42.32%) | (129.82%) | — | 0.00% | (29.07%) | (106.30%) | 0.20% | (22.04%) |
Free Cash Flow Yield |
— | — | (43.75%) | (117.63%) | — | (5.15%) | (32.95%) | (78.82%) | (5.07%) | (22.53%) |
Revenue per Share |
0.00 | 0.00 | 0.34 | 0.11 | 0.00 | 3.16 | 0.10 | (0.54) | 2.10 | 0.36 |
Operating CF per Share |
(17.03) | (14.16) | (9.62) | (7.67) | (4.67) | (0.86) | (2.29) | (2.25) | (0.23) | (1.79) |
Capex per Share |
(0.06) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.03) | 0.00 | (0.02) | 0.00 |
Free Cash Flow per Share |
(17.08) | (14.16) | (9.62) | (7.67) | (4.67) | (0.86) | (2.31) | (2.25) | (0.25) | (1.79) |
Cash per Share |
25.00 | 18.21 | 16.13 | 12.53 | 7.53 | 8.73 | 6.22 | 4.18 | 4.05 | 2.74 |
Shareholders Equity per Share |
24.23 | 16.10 | 7.51 | 4.13 | 4.69 | 8.91 | 6.81 | 3.87 | 3.93 | 2.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
24.23 | 16.10 | 7.51 | 4.13 | 4.69 | 8.91 | 6.81 | 3.87 | 3.93 | 2.66 |
Free Cash Flow |
(18.34) | (16.70) | (12.08) | (11.67) | (15.30) | (4.42) | (12.10) | (11.88) | (1.31) | (9.76) |
Working Capital |
25.88 | 18.87 | 16.32 | 14.67 | 18.75 | 40.76 | 32.46 | 20.23 | 20.81 | 14.35 |
Capital Expenditures |
(0.06) | — | — | — | — | (0.01) | (0.13) | (0.01) | (0.09) | — |
Net Current Asset Value |
25.88 | 18.87 | 9.39 | 6.26 | 15.32 | 39.47 | 32.23 | 20.23 | 20.81 | 14.35 |
EV/EBIT |
— | — | 0.00 | 0.15 | — | 14.39 | 0.00 | 0.23 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.27 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | 27.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.48 | (0.95) | (9.46) | (41.36) | 0.00 | 71.67 | (0.86) | (7.96) | (3.98) | (1.27) |
Cash ROIC |
(34.70%) | (41.29%) | (30.24%) | (35.89%) | (33.56%) | (4.78%) | (17.75%) | (28.01%) | (3.08%) | (33.19%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.25 | 6.00 | 0.00 | 130.33 | 3.05 | (42.97) | 84.77 | 2.88 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.09 | 1.69 | 1.69 | 0.03 | 0.01 | 0.12 | 0.16 | 0.07 | 0.13 | 0.69 |
Average Payables |
0.38 | 0.42 | 0.63 | 0.93 | 1.39 | 1.44 | 0.94 | 1.00 | 0.83 | 0.62 |
Average Assets |
36.36 | 26.33 | 23.09 | 20.26 | 22.51 | 38.92 | 45.01 | 30.27 | 22.76 | 19.76 |
Average Common Equity |
34.00 | 22.50 | 14.21 | 7.86 | 10.81 | 30.46 | 40.60 | 28.00 | 20.68 | 17.74 |
Columns are period end dates